Wenqiang Liu*

Hengenix Biotech, Inc., Milpitas, CA, United States

*Corresponding Author: Wenqiang Liu, Hengenix Biotech, Inc., Milpitas, CA, United States.

Received: November 22, 2021; Published: December 01, 2021

Abstract

Antibody drugs have become the most rapidly growing marketed drug products within recent years. During January 1 to November 12, 2021, 11 antibody therapeutics were granted first approval in either the US or EU. And as of November 12, 2021, 18 investigational antibody therapeutics are in regulatory review in either the US or EU. More than 130 antibody drug products have been approved globally until today, of which most are in liquid solutions and ~27% are lyophilized powders. Antibody therapies are usually highly specific to their targets and with better safety profile comparing to traditional small-molecule drugs. However, antibody-based drugs usually have short pharmacokinetic properties (couple days to weeks), low tissue penetration, and stability issues during manufacturing, transport, storage, and formulation which limit their clinical use. The routes of administration are mainly subcutaneous or intravenous infusion with several intravenous bolus, intravitreal, and intramuscular in drug products so far. There are many opportunities in developing antibody formulations and delivery systems for better patient compliance, cost savings and lifecycle management.

Citation

Citation: Wenqiang Liu. “Routes of Antibody Drug Delivery and Challenges". Acta Scientific Pharmaceutical Sciences 6.1 (2022): 01-02.

Copyright

Copyright: © 2022 Wenqiang Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.